NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
 - EconoTimes)
NEW ORLEANS, Feb. 10, 2017 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., reminds investors that they have until April 4, 2017 to file lead plaintiff applications in a securities class action lawsuit against Stemline Therapeutics, Inc. (Nasdaq:STML), if they purchased the Company’s securities pursuant and/or traceable to Stemline’s secondary public offering on or about January 20, 2017 and/or between the expanded period of January 6, 2017 and February 1, 2017, inclusive (the “Class Period”). The action is pending in United States District Court for the Southern District of New York.
What You May Do
If you purchased shares of Stemline and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by April 4, 2017.
About the Lawsuit
Stemline and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The alleged false and misleading statements and omissions include, but are not limited to, that: (i) a cancer patient in a Stemline clinical trial tied to SL-401 died from a severe side effect on January 18, 2017, immediately prior to the Company’s secondary offering; and (ii) Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 206 Covington St. Madisonville, LA 70447
